Table 1.
Baseline clinical trial characteristics
| Variables | Number of trials | (%) | |
|---|---|---|---|
| Phase | II | 10 | (14) |
| III | 57 | (80) | |
| Unspecified | 4 | (6) | |
| Type of Tumor | Breast | 13 | (18) |
| Genitourinary | 10 | (14) | |
| Gastrointestinal | 6 | (8) | |
| Lung | 10 | (14) | |
| Other solid tumors | 14 | (20) | |
| Hematological | 12 | (17) | |
| Any cancer | 6 | (8) | |
| Publication | JCO | 52 | (73) |
| NEJM | 17 | (24) | |
| Lancet | 2 | (3) | |
| Registry | Clinicaltrials.gov | 62 | (87) |
| ISRCT | 5 | (7) | |
| EudraCT | 2 | (3) | |
| ANZCTR | 1 | (1) | |
| NTR | 1 | (1) | |
| Type of Intervention | Chemotherapy | 22 | (31) |
| Targeted therapy | 26 | (37) | |
| Chemotherapy and radiation | 6 | (8) | |
| Surgery or radiation | 6 | (8) | |
| Supportive care | 11 | (15) | |
| Trial Initiation Period | 1994–2005 | 30 | (42) |
| 2006–2010 | 41 | (58) | |
| Trial Result | Negative | 37 | (52) |
| Positive | 34 | (48) | |
| Funding Source | Non-pharma | 33 | (46) |
| Pharma | 38 | (54) | |
| Length of Trial | < 3 years | 30 | (42) |
| ≥ 3 years | 41 | (58) | |
| Protocols with endpoints | Primary endpoints | 71 | (100) |
| Secondary endpoints | 71 | (100) | |
| Exploratory endpoints | 28 | (39) |
Abbreviations: JCO Journal of Clinical Oncology, NEJM New England Journal of Medicine, ISRCT International Standard Randomized Control Trial, EudraCT European Clinical Trials Database, ANZCTR Australian New Zealand Clinical Trial Registry, NTR Netherlands National Trial Register